Results 111 to 120 of about 26,674 (238)

Bone Marrow Failure as an Underrecognized Feature of KAT6A Syndrome

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT KAT6A syndrome (Arboleda–Tham syndrome) is a rare disorder caused by heterozygous pathogenic variants in KAT6A, a histone acetyltransferase essential for chromatin remodeling and hematopoietic stem cell function. While neurodevelopmental features are well established, hematologic manifestations are underrecognized.
Ye Jee Shim, Bruce Crooks, Hyoung Jin Kang, Kyung Taek Hong, Jung Yoon Choi, Hye Ra Jung, Chang Ahn Seol, Rinu Mathew, Yigal Dror   +8 more
wiley   +1 more source

Disease Burden, Patient Experiences, and Unmet Needs in Those With Rheumatoid Arthritis Initiating a Third Advanced Therapy: Insights From 20 Years of Real‐World Data

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Objective Despite advances in rheumatoid arthritis (RA) treatment, a considerable proportion of patients exhibit refractory disease, prompting the need for a comprehensive understanding of refractory RA. We aimed to analyze the burden and patient experiences associated with initiation of a third biologic or targeted synthetic disease‐modifying ...
Kristin Wipfler, Sofia Pedro, Bobby Kwanghoon Han, Urbano Sbarigia, Federico Zazzetti, Anna Sheahan, Patti Katz, Kaleb Michaud   +7 more
wiley   +1 more source

Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [PDF]

, 2016
Objectives To summarize and compare the benefits and harms of biological agents used as monotherapy for rheumatoid arthritis (RA) in order to inform decisions for patients who are intolerant to conventional DMARD therapy.
Bliddal, Henning, Boers, Maarten, Choy, Ernest Ho Sing, Christensen, Robin, Dossing, Anna, Furst, Daniel E., Hansen, Michael S., Kristensen, Lars E., Lorenzen, Tove, Singh, Jasvinder A., Suarez-Almazor, Maria E., Tarp, Simon, Østergaard, Mikkel   +12 more
core   +2 more sources

Applications and Challenges of Digital Health in Rheumatology

iNew Medicine, EarlyView.
Xiao‐Xiao Li, Xue‐Er Cheng, Ming‐Ming Zhang, Peng Wang, Hai‐Feng Pan   +4 more
wiley   +1 more source

The Association Between Serum Immunoglobulin G Titers Against Porphyromonas gingivalis and Chronic Kidney Disease in Patients With Rheumatoid Arthritis and Periodontitis: A Retrospective Cohort Study

Clinical and Experimental Dental Research, Volume 12, Issue 1, February 2026.
ABSTRACT Objectives Chronic kidney disease (CKD) is relatively common in patients with rheumatoid arthritis (RA). Periodontitis and periodontopathic Porphyromonas gingivalis are risk factors for CKD. However, the association of serum immunity to P. gingivalis and its peptidylarginine deiminase (PPAD), as well as periodontitis severity, with CKD in ...
Tetsuo Kobayashi, Satoshi Ito, Noriko Sugita, Akira Murasawa, Hajime Ishikawa, Koichi Tabeta   +5 more
wiley   +1 more source

Psoriasiform Drug Eruption Caused by Abatacept: Immunohistochemical Investigation of STAT Signaling

Case Reports in Dermatology, 2015
Abatacept is a biological immune modifier that is used for the treatment of rheumatoid arthritis. Although psoriasiform drug eruption is reported as one of the cutaneous adverse effects of abatacept, the precise mechanisms are not fully understood.
Kayo Tanita, Taku Fujimura, Aya Kakizaki, Sadanori Furudate, Yoshiyuki Kusakari, Setsuya Aiba   +5 more
doaj   +1 more source

Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases [PDF]

, 2015
BACKGROUND: The number of individuals with autoimmune inflammatory rheumatic diseases (AIIRDs) treated with immunosuppressive drugs is increasing steadily.
Bühler, S., Eperon, G., Hatz, C., Kyburz, D., Ribi, C., Siegrist, C.A., van Gompel, F., Visser, L.G.   +7 more
core   +4 more sources

Model‐Informed Abatacept Dose Recommendation in Pediatric Patients With Acute Graft Versus Host Disease

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract This study uses a population pharmacokinetic (PPK) approach to provide abatacept dosing recommendations in pediatric patients 2 to < 6 years of age receiving unrelated donor hematopoietic stem cell transplantation (HSCT) due to hematologic malignancies (HMs), for the prophylaxis of acute graft‐versus‐host disease (aGVHD).
Rui Zhong, Kelly Maxwell, Julie Passarell, Bindu Murthy, Urvi Aras, Daphne Williams   +5 more
wiley   +1 more source

Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice

BMC Pharmacology and Toxicology, 2019
Background Abatacept is increasingly used for rheumatoid arthritis (RA) and juvenile idiophathic arthritis (JIA) treatment. However little is known about the risk of hepatotoxicity.
Sultan M. Almogairen
doaj   +1 more source

Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis [PDF]

, 2018
Background Few risk factors have been identified for the development of calcinosis among patients with Juvenile Dermatomyositis, and currently no clinical phenotype has been associated with its development.
Al-Hammadi, Noor, Baszis, Kevin W, CARRA Legacy Registry Investigators,, Dharnidharka, Vikas R, Orandi, Amir B   +4 more
core   +2 more sources